HER-2阳性乳腺癌分子靶向治疗进展(6)
[21]Fehrenbacher L.Adjuvant trastuzumab did not improve out-comes for patients with her2-low breast cancer：2017 San Antonio Breast Cancer Symposium[C].San Antonio，2017，Abstract：GS1-02.[22]Cameron D，Piccart-Gebhart MJ，Gelber RD，et al.11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer： final analysis of the HERceptin Adjuvant (HERA) trial[J].Lancet ......
您现在查看是摘要页，全文长 3238 字符。